FDA decision: Bepirovirsen by GlaxoSmithKline (this year)
As of Mon, 19 Oct 2026 22:29:12 UTC, Kalshi traders price Yes (96.0%). The market has $4K in volume and closes on Fri, 01 Jan 2027.
Updated:
Current odds
| Outcome | Chance | Yes price | No price |
|---|---|---|---|
| Yes | 96.0% | 96.0¢ | 4.0¢ |
Market details
- Venue: Kalshi
- Volume: $4K
- Liquidity: $4K
- Closes:
Resolution rules
If the FDA's decision on Bepirovirsen by GlaxoSmithKline in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Bepirovirsen is an experimental antiviral medicine developed by GlaxoSmithKline that is designed to clear the hepatitis B virus from the body rather than just keeping it asleep. It belongs to a modern class of gene-silencing therapies that hunt down and destroy the virus's replication instructions. This is similar to intercepting and shredding a virus’s blueprints before its cell-invading factory has a chance to read them and build new viral copies.
Sources
Related markets
- S&P close price end of 2026?
- Nasdaq-100 price on Sep 30, 2026 at 4pm EDT?
- Nasdaq-100 close price end of 2026?
- When will Anthropic officially announce an IPO?
- Who will successfully take over Warner Brothers?
- When will Apple release the iPhone 18?
DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.